Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4612664 | 0.77 | ACLY (0.62) | ACLYTSHRCA1CA2HTT | |
| SCHEMBL10068284 | 0.77 | ACLY (0.62) | ACLYCA1CA2HTT | |
| SCHEMBL12626450 | 0.75 | ACLY (0.59) | ACLYTSHRCA1CA2ALDH1A1 | |
| SCHEMBL10037141 | 0.73 | ACLY (0.58) | ACLYCA1CA2ALDH1A1 | |
| SCHEMBL4611818 | 0.70 | ACLY (0.54) | ACLYTSHRCA1CA2ALDH1A1 | |
| SCHEMBL5307105 | 0.70 | KMT2A (0.69) | ACLYSMN1; SMN2TSHRHTTALDH1A1 | |
| SCHEMBL4610558 | 0.70 | ACLY (0.53) | ACLYCA1CA2 | |
| SCHEMBL22004411 | 0.68 | ACLY (1.00) | ACLYSMN1; SMN2 | |
| SCHEMBL14544494 | 0.68 | CA1 (0.66) | ACLYTSHRCA1CA2ALDH1A1 | |
| SCHEMBL22004196 | 0.68 | ACLY (1.00) | ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102616-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885SMN1; SMN2 4811/4885TSHR 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.